{"entity":{"id":"nct06172478","kind":"trial","name":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 2 trial of Patritumab deruxtecan in melanoma and cervical cancer, run by Daiichi Sankyo, now recruiting.","summary":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors is a phase 2 interventional study registered as NCT06172478 by Daiichi Sankyo, with 740 participants planned, started 2024-02-26 and due to reach its primary completion in 2027-09-01. Interventions recorded: HER3-DXd. Conditions listed: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06172478","url":"https://clinicaltrials.gov/study/NCT06172478"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","cervical","endometrial","prostate","nsclc"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["patritumab-deruxtecan"],"companies":["daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06172478","phase":"2","setting":"HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors","sponsor":"Daiichi Sankyo","participation":[{"nct":"NCT06172478","source":"https://clinicaltrials.gov/study/NCT06172478","fetchedAt":"2026-10-07T16:54:18.114Z","studySha256":"1cfe2ccf574d00ae20222ecf523be75e830355c96dc142b9617033eef744673d","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-01","leadSponsor":"Daiichi Sankyo","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":740,"enrolmentType":"ESTIMATED","siteCount":94,"recruitingSiteCount":90,"countries":["Australia","Belgium","Canada","China","France","Germany","Hungary","Italy","Japan","Netherlands","Norway","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2024-02-26","startedType":"actual","enrolled":740,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06172478/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}]}}